Villya says oral peptide platform keeps semaglutide stable in gastric conditions

Villya disclosed lab data on June 22, 2026, showing its proprietary delivery platform preserved semaglutide and improved insulin solubility in simulated stomach conditions. The findings could support future oral versions of GLP-1 drugs and insulin, two drug classes that are difficult to deliver by mouth.

Why it matters: - Villya is aiming at one of the biggest barriers in metabolic medicine: getting fragile peptide drugs like semaglutide and insulin to survive the stomach and be absorbed orally. - If the platform translates beyond the lab, it could reduce dosing, improve convenience and expand access to oral treatments for obesity, type 2 diabetes and insulin replacement therapy. - The company’s work sits in a large commercial market where injectable GLP-1 drugs have succeeded, but oral delivery remains a major unmet need.

What happened: - Villya announced new laboratory data on June 22, 2026, from Melbourne, Florida. - The data support the company’s proprietary oral peptide delivery platform covered by international patent application WO2025064695A1, titled “Compositions and Methods for Improving the Solubility of Insulin, Insulin Analogs, and A1C or Glucose Regulatory Compounds.” - Villya said the platform improved solubility for insulin and GLP-1 drugs, including semaglutide, while protecting the molecules from degradation in simulated gastric conditions. - High-performance liquid chromatography showed semaglutide remained intact after prolonged exposure to simulated stomach acid. - William Miller, founder and CEO of Villya, said the HPLC data suggest the technology can maintain semaglutide stability in simulated gastric conditions for extended periods.

The details: - Villya said the technology produced enhanced solubility characteristics in semaglutide formulations. - The company reported preservation of semaglutide molecular integrity after up to four hours in simulated gastric fluid. - Chromatographic profiles showed minimal structural degradation during the gastric exposure testing. - Villya said comparative lab observations suggested better performance than conventional semaglutide formulations tested under similar conditions. - The company described the platform as using molecular encapsulation and solubility-enhancement mechanisms designed to shield active ingredients during gastrointestinal transit. - Villya said the results could support lower doses to achieve equivalent or better therapeutic outcomes. - Semaglutide is a GLP-1 receptor agonist used to treat obesity and type 2 diabetes. - Oral delivery of peptide drugs has long been limited by degradation in the gastrointestinal tract and poor absorption.

Between the lines: - The data are preclinical and come from simulated gastric testing, so they do not show that the platform will work in patients. - The strongest claim here is stability, not clinical efficacy, and that distinction matters for oral peptide development. - Villya’s patent position suggests the company is trying to build both a delivery platform and a defensible intellectual property moat around oral formulations. - The company is also framing the technology as a broader platform for multiple therapeutic classes, not only semaglutide.

What's next: - Villya plans expanded analytical studies, additional pharmacokinetic testing and future animal studies to assess oral bioavailability and therapeutic performance. - The company is also seeking strategic partnerships with pharmaceutical companies focused on oral peptide delivery and metabolic medicines. - Villya said the platform could have applications in obesity management, type 2 diabetes, insulin replacement therapies, metabolic disease and other peptide-based therapeutics.

The bottom line: - Villya’s early data suggest its oral delivery platform can help peptide drugs survive stomach conditions, but the real test will be whether the chemistry holds up in animals and, later, in humans.